This was the stock's fourth consecutive day of gains.
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...
Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...
While America retains a gold standard for airline safety, there are stresses on the US air travel system that have ...
It will be sold under the brand name Journavx ... according to a study by Vertex Pharmaceuticals, the company that developed the new drug; about half those prescriptions are written for opioid ...
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results